Last update 01 Nov 2024

SLAMF2 x Tubulin

Basic Info

Related Targets
SLAMF2Tubulin

Related

1
Drugs associated with SLAMF2 x Tubulin
SGN-CD48A
Target
SLAMF2 x Tubulin
Mechanism
SLAMF2 inhibitors [+1]
Active Org.-
Originator Org.
Seagen Inc.Seagen Inc.
Active Indication-
Inactive Indication
Multiple Myeloma
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with SLAMF2 x Tubulin
NCT03379584 / TerminatedPhase 1
A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma
100 Clinical Results associated with SLAMF2 x Tubulin
Login to view more data
100 Translational Medicine associated with SLAMF2 x Tubulin
Login to view more data
0 Patents (Medical) associated with SLAMF2 x Tubulin
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free